Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
Rosenthal J, Naqvi AS, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, Rheingold SR, Pillai V. Rosenthal J, et al. Among authors: pillai v. Am J Hematol. 2018 Nov;93(11):E352-E355. doi: 10.1002/ajh.25235. Epub 2018 Sep 9. Am J Hematol. 2018. PMID: 30058145 Free article. No abstract available.
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR. Pillai V, et al. Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692. Blood Adv. 2019. PMID: 31738832 Free PMC article.
Hematopathologic Correlates of CAR T-Cell Therapy.
Dolan JG, Paessler ME, Rheingold SR, Pillai V. Dolan JG, et al. Among authors: pillai v. Clin Lab Med. 2021 Sep;41(3):325-339. doi: 10.1016/j.cll.2021.03.012. Epub 2021 Jul 1. Clin Lab Med. 2021. PMID: 34304768 Free article. Review.
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Myers RM, et al. Among authors: pillai v. J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12. J Clin Oncol. 2022. PMID: 34767461 Free PMC article.
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Lamble AJ, et al. Among authors: pillai v. Blood Adv. 2023 Feb 28;7(4):575-585. doi: 10.1182/bloodadvances.2022007423. Blood Adv. 2023. PMID: 35482927 Free PMC article.
Loss of surface CD3 expression in allogeneic CAR T-cells.
Margolskee E, Pillai V. Margolskee E, et al. Among authors: pillai v. Am J Hematol. 2020 Sep;95(9):1115-1116. doi: 10.1002/ajh.25775. Epub 2020 Mar 20. Am J Hematol. 2020. PMID: 32129509 Free article. No abstract available.
491 results